LURIE CANCER CENTER
Multidisciplinary Head & Neck Symposium
December 2-3, 2022 | Join us in Chicago!

CONFERENCE CHAIR
Sandeep Samant, MD
Chief, Head & Neck Surgery
Northwestern Medicine

CO-CHAIRS
Jochen Lorch, MD, MSc
Professor, Hematology & Oncology
Bharat Mitttal, MD
Chair, Radiation Oncology

SCIENTIFIC PLANNING COMMITTEE
Laila Gharzai, MD, Radiation Oncology
Urjeet Patel, MD, Head & Neck Surgery
Katelyn Stepan, MD, Head & Neck Surgery

Prentice Women’s Hospital | 250 E. Superior St, Chicago, Illinois

LEARN MORE & REGISTER:
cancer.northwestern.edu/headneck

QUESTIONS:
cancer@northwestern.edu
Friday, December 2, 2022

7:45 a.m.  
Opening Remarks  
Sandeep Samant, MD

8:00 a.m.  
Oral Cavity I  
Moderator: Uma Duvvuri, MD, PhD
Neoadjuvant Immunotherapy for Oral Cavity Cancers  
Ravindra Uppaluri, MD, PhD
SNB versus END: Update on NRG-HN006  
Stephen Lai, MD, PhD
Molecular Margins in Head and Neck Cancer: Challenges and Future Directions  
Sidharth Puram, MD, PhD
Recent Developments in Treatment and Science of Salivary Cancer  
Alan Ho, MD, PhD
Q&A  
Alan Ho, MD, PhD; Stephen Lai, MD, PhD; Sidharth Puram, MD, PhD; Ravindra Uppaluri, MD, PhD

9:15 a.m.  
Oral Cavity II  
Moderator: Urjeet Patel, MD
Radiation Therapy for Oral Cavity Cancer  
Laila Gharzai, MD
Reconstruction for OCC  
Katelyn Stepan, MD
Immediate Reconstruction & Rehabilitation of Oral Cavity Defects  
Mark Hutten, DDS; Alexis B. Olsson, DDS
Case Discussion  
Fred Baik, MD; Bhisham Chera, MD; Laila Gharzai, MD; Mark Hutten, DDS; Alexis B. Olsson, DDS

10:30 a.m.  
Break

10:45 a.m.  
Oropharynx I  
Moderator: Chris Holsinger, MD
Emerging Role of ctDNA in the Management of OPC  
Bhisham Chera, MD
Surgical De-intensification for OPC: Current State and Future Directions  
Uma Duvvuri, MD, PhD
Optimizing Adjuvant Therapy for HPV OPC  
Dan Ma, MD
Frontiers in Surgical Management of HPV OPC  
Sandeep Samant, MD
Case Discussion  
Bhisham Chera, MD; John De Almeida, MD, MSc; Uma Duvvuri, MD, PhD; Dan Ma, MD; PhD; Nabil Saba, MD; Sandeep Samant, MD

11:00 a.m.  
Oropharynx II  
Moderator: Sandeep Samant, MD
Emerging Role of ctDNA in the Management of OPC  
Bhisham Chera, MD
Surgical De-intensification for OPC: Current State and Future Directions  
Uma Duvvuri, MD, PhD
Optimizing Adjuvant Therapy for HPV OPC  
Dan Ma, MD
Frontiers in Surgical Management of HPV OPC  
Sandeep Samant, MD
Case Discussion  
Bhisham Chera, MD; John De Almeida, MD, MSc; Uma Duvvuri, MD, PhD; Dan Ma, MD; PhD; Nabil Saba, MD; Sandeep Samant, MD

12:15 p.m.  
Lunch

1:15 p.m.  
Nasopharynx/Paranasal Sinus  
Moderator: Alan Ho, MD, PhD
Update on Nasopharyngeal Cancer  
Sue Yom, MD, PhD
Immunotherapeutic Approaches in Nasopharyngeal Cancer  
Nabil Saba, MD
Management of Locally Advanced Paranasal Sinus Malignancy  
Sandeep Samant, MD

2:15 p.m.  
Melanoma  
Moderator: Sunandana Chandra, MD
Update on Systemic Therapy for Melanoma  
Daniel Olson, MD
Surgical Management of Melanoma in the Post-MSLT-II Era  
Jeffrey Wayne, MD
Case Discussion  
Jennifer Choi, MD; Daniel Olson, MD; Tarita Thomas, MD, PhD; Ravindra Uppaluri, MD, PhD; Jeffrey Wayne, MD

3:00 p.m.  
Break

3:45 p.m.  
Thyroid  
Moderator: Whitney Liddy, MD
New Drug Therapies for Management of Thyroid Malignancies  
Jochen Lorch, MD
Molecular Testing Update  
Ioannis Papagiannis, MD
Extent of Surgery for Differentiated Thyroid Cancer  
Cord Sturgeon, MD
Management of Locoregionally Advanced Thyroid Cancer  
Mark Zafereo, MD
Case Discussion  
Jochen Lorch, MD; Ioannis Papagiannis, MD; Cord Sturgeon, MD; Mark Zafereo, MD

5:15 p.m.  
Adjourn
Saturday, December 3, 2022

8:00 a.m.  **Oropharynx II**

- **Moderator:** Jason Newman, MD
- **Cooperative Group Efforts in Treatment De-intensification for HPV OPC** Barbara Burtness, MD
- **Proton Beam Therapy in OPC: Potential, Promise, and Pitfalls** Eric Nesbit, MD
- **Management of the Contralateral Neck** John De Almeida, MD, MSc
- **Heterogeneity in HPV Expression and Risk-Stratified (De-)Escalation of Oropharyngeal Cancer Treatment** Sidharth Puram, MD, PhD
- **Case Discussion** Barbara Burtness, MD; John De Almeida, MD, MSc; Jochen Lorch, MD; Eric Nesbit, MD; Sidharth Puram, MD; PhD; Wade Thorstad, MD

9:40 a.m.  Break

9:55 a.m.  **Carcinoma Unknown Primary**

- **Moderator:** Urjeet Patel, MD
- **ASCO Guidelines:** Uma Duvvuri, MD, PhD
- **Radiation Planning for CUP** Wade Thorstad, MD
- **FIND Trial** John De Almeida, MD, MSc
- **Case Discussion** Borislav Alexiev, MD; Barbara Burtness, MD; John De Almeida, MD, MSc; Uma Duvvuri, MD, PhD; Chris Holsinger, MD, FACS; Wade Thorstad, MD

11:00 a.m.  **Nonmelanoma Skin Cancer**

- **Moderator:** Sunandana Chandra, MD, MS
- **Systemic Therapy Updates on Non melanoma skin cancers including Merkel cell, CSCC, BCC** Sunandana Chandra, MD, MS
- **Role of Mohs surgery in NMSCs** Simon Yoo, MD
- **When do Cutaneous Squamous Carcinoma Patients Need to See a Head and Neck Surgeon?** Jason Newman, MD
- **Histopathologic Evaluation of High Risk Non-Melanoma Skin Cancers: What Do We Need to Know from the Pathology Report?** Borislav Alexiev, MD
- **Case Discussion** Borislav Alexiev, MD; Dan Ma, MD; Bharat Mittal, MD; Jason Newman, MD; Sue Yom, MD, PhD

12:15 p.m.  Lunch

1:15 p.m.  **Salvage Therapy for Recurrent Metastatic Disease**

- **Moderator:** Lalita Gharzai, MD
- **Systemic Therapy for Recurrent Metastatic Disease** Frank Worden, MD
- **Radiation Principles in Management of Recurrent Metastatic Disease** Michelle Mierzwa, MD
- **Case Discussion** Uma Duvvuri, MD, PhD; Michelle Mierzwa, MD; Kerstin Stenson, MD; Katelyn Stepan, MD; Frank Worden, MD

2:15 p.m.  **Larynx/Hypopharynx**

- **Treatment Selection in Larynx Cancer** John Cramer, MD
- **Conservation Laryngeal Surgery in 2022: Upholding the Noble Tradition, Blazing New Trails** Chris Holsinger, MD, FACS
- **Systemic Therapy for Larynx and Hypopharynx Cancer** Nabil Saba, MD
- **Case Discussion** John Cramer, MD; Chris Holsinger, MD, FACS; Bharat Mittal, MD; Nabil Saba, MD; Sue Yom, MD, PhD

3:15 p.m.  Adjourn

---

**SYMPOSIUM REGISTRATION FEES**

<table>
<thead>
<tr>
<th></th>
<th>DISCOUNTED</th>
<th>REGULAR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physicians</td>
<td>$275</td>
<td>$325</td>
</tr>
<tr>
<td>Dentists</td>
<td>$275</td>
<td>$325</td>
</tr>
<tr>
<td>Nurses, Speech Pathologists</td>
<td>$125</td>
<td>$175</td>
</tr>
<tr>
<td>Residents, Fellows</td>
<td>$125</td>
<td>$175</td>
</tr>
<tr>
<td>Industry Representatives</td>
<td>$500</td>
<td>$550</td>
</tr>
</tbody>
</table>

Advance registration is encouraged, as space and materials are limited. To qualify for the discounted registration fee, Lurie Cancer Center must receive registration information and payment by October 14, 2022. The registration fee includes conference tuition, CME credits, materials, two breakfasts, two lunches, and refreshments during breaks.

If you cancel your participation in this conference, your registration fee less a $50 administrative fee, will be refunded when written notification is received by October 14, 2022. No refunds will be made after that date, however, you may transfer your registration to a colleague.
LEARNING OBJECTIVES

1. Apply a multidisciplinary approach to the treatment of head and neck cancers
2. Assess state-of-the-art therapeutic options for the treatment of head and neck cancer, including:
   i. Minimally invasive surgical treatment, including robotic surgery and sentinel lymph node mapping
   ii. Benefits and limitations of proton therapy in the treatment of head and neck cancer
   iii. Incorporation of immunotherapy for treatment of advanced head and neck cancer
   iv. Virtual surgical planning for reconstruction of surgical defects
3. Discuss future directions in treatment of head and neck cancer based on the latest basic science and clinical developments, including:
   i. De-escalation of therapy in the management of oropharyngeal cancer
   ii. Application of circulating tumor DNA as a biomarker for HPV-associated oropharyngeal cancer
   iii. Molecular assessment of surgical margin
   iv. Risk-stratification of head and neck cancer
   v. Advances in treatment of nasopharyngeal cancer
4. Apply current treatment guidelines to patients with head and neck cancers

TARGET AUDIENCE

The target audience for this activity includes medical oncologists, radiation oncologists, surgeons, dentists, speech pathologists and allied health professionals treating or interested in treating those with head and neck cancer.

ACCREDITATION STATEMENT

The Northwestern University Feinberg School of Medicine is accredited by the Accreditation Council for Continuing Medical Education ( ACCME ) to provide continuing medical education for physicians.

CREDIT DESIGNATION

The Northwestern University Feinberg School of Medicine designates this live activity for a maximum of 13.75AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS

The American Academy of Nurse Practitioners and the American Nurses Credentialing Center accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

This symposium is made possible, in part, by the generous endowed gift of Harry Staffileno, Jr., DDS, MS, to support oncology-related oral health at Northwestern Medicine.